Citizens JMP lowered the firm’s price target on Intellia Therapeutics (NTLA) to $21 from $29 and keeps an Outperform rating on the shares. Intellia disclosed that the 80-year-old patient has passed away following reports of a Grade 4 liver injury in a Nex-Z patient and the FDA’s clinical hold on the MAGNITUDE trial, the analyst tells investors in a research note. Citizens has removed ATTR from its model.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target lowered to $14 from $24 at Barclays
- Cautious Hold Rating on Intellia Therapeutics Amid Safety Concerns and Regulatory Uncertainty
- Intellia Therapeutics downgraded to Underweight from Neutral at JPMorgan
- Intellia Therapeutics: Buy Rating Affirmed Amid HAE Program Optimism Despite ATTR Setback
- Cathie Wood Pours into Veracyte Stake ahead of Earnings Beat, Slashes Biotech Holdings